Roche has announced that its investigational oral selective estrogen receptor degrader (SERD) giredestrant failed to demonstrate improved progression-free survival compared to standard endocrine therapy in previously treated hormone receptor (HR)-positive, HER2-negative breast cancer patients.
The results from the phase 2 acelERA trial mark another setback for the emerging oral SERD drug class, following the recent failure of Sanofi's amcenestrant in the similar AMEERA-3 trial. Despite the primary endpoint miss, Roche reported encouraging efficacy signals in patients with higher estrogen receptor activity dependence.
Trial Design and Results
The acelERA study evaluated giredestrant against physician's choice of endocrine therapy in patients with advanced HR-positive, HER2-negative breast cancer who had received prior treatment. Similar to Sanofi's AMEERA-3 trial, the study design did not specifically target patients with ESR1 mutations, which are known to confer resistance to standard hormonal therapies.
Implications for Oral SERD Development
The trial outcome raises important questions about the future development strategy for oral SERDs. Recent data from the EMERALD trial of Radius Health and Menarini's elacestrant showed a 30% reduction in progression-free survival, with particularly strong results in the ESR1-positive patient subgroup, suggesting that patient selection could be crucial for success in this drug class.
Ongoing Development Program
Despite this setback, Roche maintains an active development program for giredestrant. The company previously reported positive results from the coopERA study, where giredestrant outperformed anastrozole as neoadjuvant therapy in post-menopausal women with early-stage HR-positive, HER2-negative breast cancer. Additional studies are ongoing to evaluate giredestrant as a first-line therapy for advanced breast cancer and in early-stage disease settings.
Company Performance Context
The trial results were disclosed as part of Roche's first-quarter financial report, which showed strong overall performance with revenues reaching CHF 16.4 billion ($17.2 billion), driven by robust diagnostic sales and growth in key therapeutic areas. The pharmaceutical division recorded a 6% increase to CHF 11.2 billion, with significant contributions from Ocrevus for multiple sclerosis and Hemlibra for hemophilia.
